

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-16 (Cancelled).

17 (Previously presented). The method of claim 19, wherein said interferon is selected from the group consisting of α -interferon, β -interferon and γ -interferon.

Claim 18 (Cancelled).

19 (Currently Amended). A method of inducing the death of ~~leukemia or lymphoma~~ acute promyelocytic leukemia cells, comprising administering to a patient in need thereof amounts of a) arsenic trioxide or a caspase inhibitor selected from the group consisting of zVAD and DEVD; and b) an interferon, effective to synergistically induce the death of ~~leukemia or lymphoma~~ acute promyelocytic leukemia cells.

Claims 20-28 (Cancelled).

29 (Previously presented). The method of claim 19, wherein said caspase inhibitor is zVAD.

30 (Previously presented). The method of claim 19, wherein said caspase inhibitor is DEVD.

Claims 31-33 (Cancelled).

34 (Currently amended). A method of treating or inhibiting acute promyelocytic leukemia, comprising administering to a patient in need thereof synergistically effective amounts of a) arsenic trioxide or a caspase inhibitor selected from the group consisting of zVAD and DEVD and b) an interferon to treat or inhibit acute promyelocytic leukemia.

Claim 35 (Cancelled).

36 (Previously presented). The method of claim 34, wherein said interferon is selected from the group consisting of α -interferon, β -interferon and γ -interferon.

37 (Previously presented). The method of claim 34, wherein said caspase inhibitor is zVAD.

38 (Previously presented). The method of claim 34, wherein said caspase inhibitor is DEVD.